Sulbactam sodium for injection / durlobactam sodium for injection co-pack | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Company
Entasis Therapeutics Inc.
Medicine type
Chemical medicine
Therapeutic area
Infectious diseases
Indications recorded in the public source
Treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) in patients aged 18 years or older caused by susceptible isolates of the Acinetobacter baumannii-calcoaceticus complex. It is not indicated for HABP/VABP caused by pathogens other than susceptible isolates of this complex (see Clinical Studies in the prescribing information). To reduce development of resistant bacteria and maintain antibacterial effectiveness, use only for infections proven or strongly suspected to be caused by susceptible bacteria. Consider available culture and susceptibility results when selecting or adjusting therapy. When these data are unavailable, local epidemiology and susceptibility patterns may guide empiric treatment.
Indication source and scope
Source date(s): 2024, 2026. Indications reflect the cited historical approval, not the complete indication set as of 2026.
Prescribing-information limitations
Complete official prescribing information obtained. The available full label is from an overseas jurisdiction; a complete current Chinese label remains unavailable. Chinese indications are supported separately by Chinese sources.
China availability status
Historical Chinese approval verified; current continuous market availability has not been checked for every product.
Overseas status
Market-by-market verification pending.
Insurance classification
Not matched in the 2025 national list; manual review pending
Insurance edition
2025 edition; effective 1 January 2026
Insurance verification notes
No match in the extracted directory is not proof of exclusion. Compound formulations still require manual review.

Sources

Open the interactive record, public price references and discussions